JP7811085B2 - セピアプテリンを含む医薬組成物及びその使用 - Google Patents

セピアプテリンを含む医薬組成物及びその使用

Info

Publication number
JP7811085B2
JP7811085B2 JP2020512443A JP2020512443A JP7811085B2 JP 7811085 B2 JP7811085 B2 JP 7811085B2 JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020512443 A JP2020512443 A JP 2020512443A JP 7811085 B2 JP7811085 B2 JP 7811085B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sepiapterin
less
salt
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532535A5 (enExample
JP2020532535A (ja
Inventor
ダニエル， イー． レヴィー，
Original Assignee
ピーティーシー セラピューティクス エムピー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス エムピー，インコーポレイテッド filed Critical ピーティーシー セラピューティクス エムピー，インコーポレイテッド
Publication of JP2020532535A publication Critical patent/JP2020532535A/ja
Publication of JP2020532535A5 publication Critical patent/JP2020532535A5/ja
Priority to JP2023088749A priority Critical patent/JP2023116556A/ja
Application granted granted Critical
Publication of JP7811085B2 publication Critical patent/JP7811085B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020512443A 2017-09-01 2018-09-04 セピアプテリンを含む医薬組成物及びその使用 Active JP7811085B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023088749A JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762553603P 2017-09-01 2017-09-01
US62/553,603 2017-09-01
US201862678069P 2018-05-30 2018-05-30
US62/678,069 2018-05-30
PCT/US2018/049359 WO2019046849A1 (en) 2017-09-01 2018-09-04 PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023088749A Division JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2020532535A JP2020532535A (ja) 2020-11-12
JP2020532535A5 JP2020532535A5 (enExample) 2021-10-14
JP7811085B2 true JP7811085B2 (ja) 2026-02-04

Family

ID=65526057

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512443A Active JP7811085B2 (ja) 2017-09-01 2018-09-04 セピアプテリンを含む医薬組成物及びその使用
JP2023088749A Pending JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023088749A Pending JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Country Status (7)

Country Link
US (3) US11752154B2 (enExample)
EP (1) EP3675863A4 (enExample)
JP (2) JP7811085B2 (enExample)
CN (1) CN111491635A (enExample)
CA (1) CA3073957A1 (enExample)
MX (1) MX2020002271A (enExample)
WO (1) WO2019046849A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
CA3165636A1 (en) 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
WO2021168206A1 (en) * 2020-02-19 2021-08-26 Musc Foundation For Research Development L-sepiapterin and methods of use for treating diseases and disorders
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
AR127191A1 (es) 2021-09-29 2023-12-27 Ptc Therapeutics Inc Composición farmacéutica de sepiapterina

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521151A (ja) 2001-07-07 2004-07-15 アストラゼネカ アクチボラグ フルベストラントを含む製剤
JP2005511494A (ja) 2001-08-07 2005-04-28 インデナ エッセ ピ ア 頭皮疾患の治療のための経口組成物
JP2008520574A (ja) 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
JP2011530540A (ja) 2008-08-12 2011-12-22 オルファ スイス ゲーエムベーハー テトラヒドロビオプテリンを含有する医薬剤形
JP2012533633A (ja) 2009-07-20 2012-12-27 ベテゲン・エルエルシー 経口投与のための安定な薬学的オメプラゾール製剤
WO2016089766A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
WO2017075256A1 (en) 2015-10-27 2017-05-04 Insys Development Company, Inc. Liquid buprenorphine formulations
JP2017515821A (ja) 2014-05-12 2017-06-15 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
JP2017114776A (ja) 2015-12-21 2017-06-29 備前化成株式会社 高度不飽和脂肪酸含有組成物及び該組成物を含有する食品
JP2019535836A (ja) 2016-11-29 2019-12-12 センサ ファーマシューティカルズ インコーポレイテッドＣｅｎｓａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． セピプテリン及びその塩の多形

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5753656A (en) 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
WO1997007236A1 (en) 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
JP2007509909A (ja) 2003-10-31 2007-04-19 アルタナ　ファルマ　アクチエンゲゼルシャフト 呼吸器疾患の治療のためのｂｈ４の使用
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) * 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
LT2262790T (lt) 2008-03-10 2017-08-25 Takeda Pharmaceutical Company Limited Benzimidazolo junginio kristalas
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
IN2012DN01453A (enExample) 2009-08-20 2015-06-05 Novartis Ag
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) * 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
WO2017218421A1 (en) 2016-06-13 2017-12-21 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
WO2018019931A1 (en) * 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521151A (ja) 2001-07-07 2004-07-15 アストラゼネカ アクチボラグ フルベストラントを含む製剤
JP2005511494A (ja) 2001-08-07 2005-04-28 インデナ エッセ ピ ア 頭皮疾患の治療のための経口組成物
JP2008520574A (ja) 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
JP2011530540A (ja) 2008-08-12 2011-12-22 オルファ スイス ゲーエムベーハー テトラヒドロビオプテリンを含有する医薬剤形
JP2012533633A (ja) 2009-07-20 2012-12-27 ベテゲン・エルエルシー 経口投与のための安定な薬学的オメプラゾール製剤
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
JP2017515821A (ja) 2014-05-12 2017-06-15 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
WO2016089766A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
WO2017075256A1 (en) 2015-10-27 2017-05-04 Insys Development Company, Inc. Liquid buprenorphine formulations
JP2017114776A (ja) 2015-12-21 2017-06-29 備前化成株式会社 高度不飽和脂肪酸含有組成物及び該組成物を含有する食品
JP2019535836A (ja) 2016-11-29 2019-12-12 センサ ファーマシューティカルズ インコーポレイテッドＣｅｎｓａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． セピプテリン及びその塩の多形

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clin. Chim. Acta. 93(2):251-62 (1979)

Also Published As

Publication number Publication date
BR112020003865A2 (pt) 2020-09-08
MX2020002271A (es) 2020-10-05
US11752154B2 (en) 2023-09-12
EP3675863A4 (en) 2021-01-27
JP2020532535A (ja) 2020-11-12
CN111491635A (zh) 2020-08-04
WO2019046849A1 (en) 2019-03-07
BR112020003865A8 (pt) 2022-08-16
US12213982B2 (en) 2025-02-04
US20200061070A1 (en) 2020-02-27
JP2023116556A (ja) 2023-08-22
US20240100054A1 (en) 2024-03-28
CA3073957A1 (en) 2019-03-07
US20250195526A1 (en) 2025-06-19
EP3675863A1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
US12213982B2 (en) Pharmaceutical compositions comprising sepiapterin and uses thereof
JP7778477B2 (ja) セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) セピアプテリン血漿曝露を増加させるための方法
JP7855033B2 (ja) テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
EP4034122B1 (en) Methods for treating hyperphenylalaninemia
HK40087700A (en) Pharmaceutically acceptable salts of sepiapterin
BR112020003865B1 (pt) Composições farmacêuticas compreendendo sepiapterina e usos das mesmas
EA042976B1 (ru) Фармацевтически приемлемые соли сепиаптерина
EA049074B1 (ru) Фармацевтически приемлемые соли сепиаптерина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230531

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230619

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260123

R150 Certificate of patent or registration of utility model

Ref document number: 7811085

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150